Clinical experience with a protease inhibitor [N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate for prevention of recurrence of carcinoma of the mouth and in treatment of terminal carcinoma
- 1 January 1984
- journal article
- Published by Elsevier BV in Journal of Maxillofacial Surgery
- Vol. 12 (4), 148-152
- https://doi.org/10.1016/s0301-0503(84)80235-0
Abstract
A protease inhibitor, (N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)-phenylacetate) methanesulfate was administered orally 3 times daily to 9 patients with squamous cell carcinoma of the oral cavity, at doses ranging from 0.6 g. to 7.2 g. Seven of 9 patients who had undergone all kinds of therapies were observed to see whether recurrence was prevented and in no case did the tumour recur. Also, in 2 terminal secondary cases tumour remission resulted. Histologically, after this therapy, carcinomatous lesions showed marked hyperkeratosis in 2 cases and the survival time in 1 case was markedly prolonged. Haematological and gastrointestinal toxicity was almost never observed at these doses.Keywords
This publication has 5 references indexed in Scilit:
- EFFECT OF A PROTEASE INHIBITOR [N,N-DIMETHYL-CARBAMOYLMETHYL 4-(4-GUANIDINOBENZOYLOXY)-PHENYLACETATE] METHANESULFATE OF THE GROWTH OF MOUSE SKIN CARCINOMA IN THE RAPID GROWING STAGEThe Journal of Dermatology, 1984
- Arrest of Growth of Ovarian Tumor by Tranexamic AcidPublished by American Medical Association (AMA) ,1977
- Effect of apotinin, EACA and heparin on growth and vasopeptide system of murphy—sturm lymphosarcomaEuropean Journal of Pharmacology, 1976
- Acid Dependent Kinin-Forming System in Mammalian Malignant and Normal TissuePublished by Springer Science and Business Media LLC ,1972
- Characterization of Pre-Kallikrein Activity in Developing Transplanted Mammalian TumorsPublished by Springer Science and Business Media LLC ,1970